Hunter syndrome is a rare genetic condition in which the body cannot break down certain complex sugar molecules called glycosaminoglycans (GAGs). Without the enzyme needed to process them, these molecules build up in cells throughout the body, gradually damaging organs, bones, airways, and sometimes the brain. The condition occurs in roughly 1 in 280,000 live births and affects boys almost exclusively.
How Hunter Syndrome Works
Every cell in your body routinely breaks down and recycles large molecules it no longer needs. One of these recycling steps requires an enzyme called iduronate-2-sulfatase, or I2S for short. This enzyme cuts a specific chemical bond on two types of GAGs: dermatan sulfate and heparan sulfate. In Hunter syndrome, mutations in the IDS gene reduce or completely eliminate I2S activity, so those sugar molecules never get broken down. They pile up inside cellular recycling compartments called lysosomes, swelling cells and eventually disrupting the function of tissues and organs throughout the body.
Because the buildup is progressive, children with Hunter syndrome typically appear healthy at birth. Symptoms emerge gradually over the first few years of life as more and more GAGs accumulate.
Why It Almost Always Affects Boys
The IDS gene sits on the X chromosome. Boys have only one X chromosome, so a single defective copy is enough to cause the disease. Girls have two X chromosomes, meaning they would need mutations on both copies to be affected, which is extremely rare. A mother who carries one mutated copy is typically unaffected herself but has a 50% chance of passing it to each son. Fathers cannot pass the condition to their sons at all, since boys inherit their single X chromosome from their mother.
Hunter syndrome has been reported in a handful of girls, but these cases are exceptional.
Two Forms: Neuronopathic and Non-Neuronopathic
Hunter syndrome exists on a spectrum, but clinicians generally distinguish two forms based on whether the brain is significantly involved.
The neuronopathic (severe) form accounts for the more devastating course. Signs of brain involvement can appear as early as age 1 but are typically detectable by age 4. Children develop cognitive decline, speech and language delays, hyperactivity (reported in about 66% of cases), behavioral problems (82%), and seizures (22%). Communication skills tend to deteriorate in a specific pattern: the ability to speak and vocalize declines before the ability to understand what others are saying. As cognitive regression deepens, many of the intense behavioral symptoms gradually subside. This form usually leads to death in the first or second decade of life, primarily from progressive airway and cardiac disease.
The non-neuronopathic (attenuated) form spares the brain. Intelligence remains normal, and behavioral issues are far less common (28%). People with this form can survive into early adulthood and beyond, though GAG accumulation still damages other organ systems over time.
Boys who completely lack functional enzyme, usually because of large gene deletions or complex rearrangements (about 17% of affected individuals), invariably develop the neuronopathic form.
Physical Signs and Symptoms
Because GAGs accumulate in nearly every tissue, Hunter syndrome affects multiple body systems at once. Many of these features overlap between the two forms, though they tend to be more pronounced and appear earlier in neuronopathic cases.
- Facial features: Coarse facial features develop in roughly 82 to 91% of children, including a broad nose, thick lips, and an enlarged tongue.
- Skeletal problems: Joint stiffness and limited range of motion affect about 85 to 88% of children regardless of form. Finger contractures, spinal curvature, and gait abnormalities are common. Short stature is typical.
- Enlarged liver and spleen: Hepatomegaly appears in 80 to 87% of cases, often causing a visibly distended abdomen.
- Heart valve disease: Present in roughly 75 to 78% of children, this is one of the leading causes of complications.
- Hernias: Inguinal or umbilical hernias occur in about 75 to 78% of affected boys, sometimes appearing in infancy before other signs are obvious.
- Hearing loss: Both conductive and sensorineural hearing loss are common.
- Airway problems: Nasal congestion, frequent respiratory infections, and breathing difficulties result from GAG deposits in the airway tissues.
- Other findings: A hoarse voice, an abnormally large head, carpal tunnel syndrome, and spinal canal narrowing round out the picture.
How Hunter Syndrome Is Diagnosed
Diagnosis involves a step-by-step process that moves from broad screening to a definitive confirmation. Pediatricians who suspect a storage disorder typically start with a urine test that measures total GAG levels. The most common method uses a dye that binds to GAGs, producing a color change measurable by a spectrophotometer. This test is inexpensive and straightforward, but it cannot tell you which type of storage disease is present.
If urine GAGs are elevated, the next step is measuring I2S enzyme activity. This can be done using white blood cells from a standard blood draw, dried blood spot cards, or skin cells obtained through a small biopsy. Low or absent enzyme activity confirms the diagnosis. Genetic testing of the IDS gene then identifies the exact mutation, which can help predict severity and is essential for genetic counseling within the family.
More advanced techniques like liquid chromatography with tandem mass spectrometry can distinguish between different types of GAGs in urine, helping differentiate Hunter syndrome from other mucopolysaccharidoses early in the process.
Newborn Screening
In 2022, the U.S. Secretary of Health and Human Services accepted a recommendation to add Hunter syndrome to the Recommended Uniform Screening Panel (RUSP) for newborns. At the time of that decision, only Illinois and Missouri were actively screening, with New York and North Carolina developing their programs. Adoption by individual states is still ongoing, so whether a baby is screened at birth depends on where they are born.
Treatment Options
The primary treatment available today is enzyme replacement therapy (ERT) with a lab-made version of the missing I2S enzyme. Approved in both the United States and the European Union, this recombinant enzyme is delivered through weekly intravenous infusions. Once in the bloodstream, it enters cells through specific receptors on cell surfaces and reaches the lysosomes, where it breaks down the accumulated GAGs.
ERT can improve several physical symptoms. It helps reduce liver and spleen size, improves walking endurance, and can slow the progression of some organ damage. However, it has a significant limitation: the enzyme molecule is too large to cross the blood-brain barrier in meaningful amounts. That means intravenous ERT does little to address the cognitive decline seen in the neuronopathic form. Researchers have been exploring direct delivery of the enzyme into the spinal fluid through intrathecal injections to try to reach the brain, and clinical trials for this approach have been underway.
Beyond ERT, treatment is largely supportive. Children often need hearing aids, physical therapy for joint stiffness, surgical repair of hernias, cardiac monitoring, and airway management. The multisystem nature of the disease means care usually involves a team of specialists.
Gene Therapy: A New Frontier
A world-first gene therapy trial is currently testing a fundamentally different approach. Scientists at University College London developed a treatment that works outside the body: a child’s white blood cells are collected and purified to isolate stem cells, which are then modified in a specialized lab to carry a working copy of the IDS gene. Those corrected stem cells are returned to the patient, where they can potentially produce the missing enzyme on an ongoing basis.
The first child to receive this treatment, a boy from California, has been described as “thriving” after the procedure. He is one of five boys worldwide enrolled in the trial, which is being conducted in collaboration with the University of Manchester. While it is far too early to draw conclusions about long-term effectiveness, the approach represents a potential shift from managing symptoms with lifelong infusions to addressing the genetic root of the disease in a single procedure.